NCT06992739 2026-04-14
PROTECT-2
The First Affiliated Hospital of Xiamen University
Phase 2 Recruiting
Clinical Trials
12 trialsNCT05578326 2026-03-30
Study of Trilaciclib and Lurbinectidin
UNC Lineberger Comprehensive Cancer Center
Phase 2 Recruiting
NCT01042379 2026-03-13
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT05874401 2025-09-04
Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan
Pharmacosmos A/S
Phase 4 Recruiting
NCT06955156 2025-05-02
Trilaciclib Combined With Anti-PD-1 Antibody and Chemotherapy in the Treatment of Locally Advanced TNBC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT06752798 2024-12-31
CCRT，LA-HNSCC
Hunan Cancer Hospital
Phase 2 Recruiting
NCT06714383 2024-12-03
Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma
Peking University People's Hospital
Phase 2 Recruiting
NCT06698965 2024-11-21
Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin
Shanghai Chest Hospital
Phase 2 Recruiting
NCT06699472 2024-11-21
A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppression in Patients with Ewing's Sarcoma Using Trilaciclib
Fudan University
Phase 2 Recruiting
NCT06490081 2024-09-24
Trilaciclib Prevents Myelosuppression With Chemoradiotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT06569459 2024-08-26
Trilaciclib Combined With Concurrent Chemoradiotherapy and Immunotherapy in the Treatment of Esophageal Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT05978648 2023-11-30
SMA-BC-002
Sun Yat-sen University
Phase 2 Recruiting